Launching new medicines - a major bottleneck in the pharma industry

Sequential launching medicines coupled with reference pricing is costing pharma companies hundreds of million dollars in forgone revenue.

OGT is proposing a simultaneous launch of new medicines in all considered markets with Optimal Global Launch Pricing.

This is a two part proposition:

- Pricing function - to keep regulatory agencies appraised of potential launch prices throughout the 12 years R&D process, with documents:

- INDP - Investigation New Drug Prices

- NDAP - New Drug Application Prices

- Actual launch optimal pricing

Next few blogs will detail and come up with live examples.